NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球惡性間皮癌市場

Global Market Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type

出版商 Persistence Market Research 商品編碼 539727
出版日期 內容資訊 英文 223 Pages
商品交期: 2-3個工作天內
價格
全球惡性間皮癌市場 Global Market Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type
出版日期: 2017年07月12日內容資訊: 英文 223 Pages
簡介

本報告提供全球惡性間皮癌市場相關調查,市場規模與成長,各藥物類型,各給藥途徑,各流通管道,各地區趨勢,競爭環境,及打入市場的主要企業簡介等彙整資料。

第1章 摘要整理

第2章 市場簡介

  • 市場定義
  • 市場分類

第3章 市場機會分析

  • 宏觀經濟因素
  • 需求與供給促進要素
  • 全球趨勢
  • 開發平台趨勢
  • 惡性間皮癌的藥物
  • 各國石棉生產
  • 各國石棉消費
  • 流行病學的資料

第4章 北美市場分析與預測

  • 簡介
  • 主要的法律規章
  • 市場趨勢
  • 各國市場規模預測
  • 各類藥物市場規模預測
  • 各給藥途徑市場規模預測
  • 各流通管道市場規模預測
  • 促進因素與阻礙因素:影響分析
  • 市場魅力度分析

第5章 南美

第6章 歐洲

第7章 亞太地區

第8章 中東、非洲

第9章 競爭環境

  • 競爭儀表板
  • 企業簡介

第10章 各地區市場分析與預測

第11章 各藥物市場分析與預測

第12章 各給藥途徑市場分析與預測

第13章 各流通管道市場分析與預測

第14章 全球市場分析與預測

目錄

An introduction to the report:

All the information pertaining to the market of this rare form of cancer is provided in our recently published report "Malignant Mesothelioma Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)." Caused due to the exposure to toxic asbestos, the occurrence of this cancer is higher in countries such as Russia and China. These two countries are pegged to represent the most lucrative markets, owing to the relatively high production of asbestos in these countries. Besides, a high consumption of asbestos in the APAC region is expected to create a sizeable opportunity for key players in this market. Our analysts have observed that the rapid substitution through generics to ease availability and affordability is the key focus area in the global malignant mesothelioma market. We have observed that the application of combination therapies is gaining traction in the market across regions. Documented evidence on the adoption of combination treatments and benefits is being made available to ease patients' journey through the treatment process. According to our analysts, there is a great need in the market to efficiently meet the requirements for the present treatment regimen. The drugs that are currently in use do not show much response rates. The malignant mesothelioma treatment market requires drugs to increase the current survival rate.

Acquisitions and collaborations are the key strategies adopted by players to develop molecules for the better treatment of malignant mesothelioma. Companies are focusing on collaborating with established research centers and other cancer drug manufacturers to develop drugs. Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

We have used our in-house epidemiology data based model to estimate the global malignant mesothelioma market numbers

Weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. Price per country is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard. We have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions. Prices considered in the models are standardized based on the average dosage used per malignant mesothelioma treatment per dosage cycle of six months. Availability of branded off-patent equivalents has been taken into consideration while calculating prices. We have adopted the bottom-up approach to forecast the malignant mesothelioma market globally. Besides this, forecasting is done using our internal proprietary model that considers different macro-economic factors, industry based demand driving factors impacting the market and the relevant forecast trends apart from disease related factors.

Market Taxonomy:

Drug Type

  • Pemetrexed
  • Cisplatin
  • Carboplatin
  • Gemcitabine
  • Vinorelbine
  • Others

Route of Administration

  • Oral
  • Parenteral

Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers

Research Methodology:

Our research methodology leverages both primary and secondary research to collect the relevant market data. We have analyzed the global malignant mesothelioma market by considering key player revenue, usage patterns, historic trends, and problems faced by oncologists, the required treatment developments, and most preferred drugs. Key opinion leaders including experienced healthcare professionals in various healthcare facilities at the country level have been considered for primary research. These estimates have been further validated with drug manufacturers, distributors, and suppliers. Extensive secondary research has been carried out to understand the epidemiology of malignant mesothelioma, treatment rate, adoption rate, regulatory scenarios, average selling price and the global reimbursement scenario by referring to published scientific literature from various databases such as the WHO, Asbestos.com, PubMed, Springer, and Wiley among many others. We have also analyzed the various companies' annual reports, investor presentations, SEC filings, reports and press releases to fetch substantial information pertaining to the market size, trends, opportunities, drivers, and restraints.

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Malignant Mesothelioma Market Opportunity Analysis

  • 3.1. Macro-Economic Factors
  • 3.2. Demand and Supply side Driver
  • 3.3. Global Trend
  • 3.4. Pipeline Snapshot
  • 3.5. Medicines in Development for Malignant Mesothelioma, 2016
  • 3.6. Asbestos Production By Country
  • 3.7. Asbestos Consumption By Country
  • 3.8. Epidemiology Data

4. North America Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025

  • 4.1. Introduction
  • 4.2. Key Regulations
  • 4.3. Regional Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Trends
  • 4.4. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
    • 4.4.1. U.S.
    • 4.4.2. Canada
  • 4.5. Market Size (US$ Mn) Forecast By Country, 2017-2025
    • 4.5.1. U.S.
    • 4.5.2. Canada
  • 4.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012-2016
    • 4.6.1. Premetrexed and combination
    • 4.6.2. Cisplatin and combination
    • 4.6.3. Carboplatin and combination
    • 4.6.4. Gemcitabine and combination
    • 4.6.5. Vinorelbine and combination
    • 4.6.6. Others combinations
  • 4.7. Market Size (US$ Mn) Forecast By Drug Class, 2017-2025
    • 4.7.1. Premetrexed and combination
    • 4.7.2. Cisplatin and combination
    • 4.7.3. Carboplatin and combination
    • 4.7.4. Gemcitabine and combination
    • 4.7.5. Vinorelbine and combination
    • 4.7.6. Others combinations
  • 4.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
    • 4.8.1. Oral
    • 4.8.2. Parenteral
  • 4.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2025
    • 4.9.1. Oral
    • 4.9.2. Parenteral
  • 4.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
    • 4.10.1. Hospital Pharmacies
    • 4.10.2. Retail Pharmacies
    • 4.10.3. Oncology Centers
  • 4.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2025
    • 4.11.1. Hospital Pharmacies
    • 4.11.2. Retail Pharmacies
    • 4.11.3. Oncology Centers
  • 4.12. Drivers and Restraints: Impact Analysis
  • 4.13. Market Attractiveness Analysis
    • 4.13.1. By Country
    • 4.13.2. By Drug Class
    • 4.13.3. By Route of Administration
    • 4.13.4. By Distribution Channel

5. Latin America Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025

  • 5.1. Introduction
  • 5.2. Key Regulations
  • 5.3. Regional Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
  • 5.4. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
    • 5.4.1. Brazil
    • 5.4.2. Mexico
    • 5.4.3. Rest of Latin America
  • 5.5. Market Size (US$ Mn) Forecast By Country, 2017-2025
    • 5.5.1. Brazil
    • 5.5.2. Mexico
    • 5.5.3. Rest of Latin America
  • 5.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012-2016
    • 5.6.1. Premetrexed and combination
    • 5.6.2. Cisplatin and combination
    • 5.6.3. Carboplatin and combination
    • 5.6.4. Gemcitabine and combination
    • 5.6.5. Vinorelbine and combination
    • 5.6.6. Others combinations
  • 5.7. Market Size (US$ Mn) Forecast By Drug Class, 2017-2025
    • 5.7.1. Premetrexed and combination
    • 5.7.2. Cisplatin and combination
    • 5.7.3. Carboplatin and combination
    • 5.7.4. Gemcitabine and combination
    • 5.7.5. Vinorelbine and combination
    • 5.7.6. Others combinations
  • 5.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
    • 5.8.1. Oral
    • 5.8.2. Parenteral
  • 5.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2025
    • 5.9.1. Oral
    • 5.9.2. Parenteral
  • 5.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
    • 5.10.1. Hospital Pharmacies
    • 5.10.2. Retail Pharmacies
    • 5.10.3. Oncology Centers
  • 5.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2025
    • 5.11.1. Hospital Pharmacies
    • 5.11.2. Retail Pharmacies
    • 5.11.3. Oncology Centers
  • 5.12. Drivers and Restraints: Impact Analysis
  • 5.13. Market Attractiveness Analysis
    • 5.13.1. By Country
    • 5.13.2. By Drug Class
    • 5.13.3. By Route of Administration
    • 5.13.4. By Distribution Channel

6. Europe Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025

  • 6.1. Introduction
  • 6.2. Key Regulations
  • 6.3. Regional Market Dynamics
    • 6.3.1. Drivers
    • 6.3.2. Restraints
  • 6.4. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
    • 6.4.1. Germany
    • 6.4.2. U.K.
    • 6.4.3. France
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. Rest of Europe
  • 6.5. Market Size (US$ Mn) Forecast By Country, 2017-2025
    • 6.5.1. Germany
    • 6.5.2. U.K.
    • 6.5.3. France
    • 6.5.4. Italy
    • 6.5.5. Spain
    • 6.5.6. Russia
    • 6.5.7. Rest of Europe
  • 6.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012-2016
    • 6.6.1. Premetrexed and combination
    • 6.6.2. Cisplatin and combination
    • 6.6.3. Carboplatin and combination
    • 6.6.4. Gemcitabine and combination
    • 6.6.5. Vinorelbine and combination
    • 6.6.6. Others combinations
  • 6.7. Market Size (US$ Mn) Forecast By Drug Class, 2017-2025
    • 6.7.1. Premetrexed and combination
    • 6.7.2. Cisplatin and combination
    • 6.7.3. Carboplatin and combination
    • 6.7.4. Gemcitabine and combination
    • 6.7.5. Vinorelbine and combination
    • 6.7.6. Others combinations
  • 6.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
    • 6.8.1. Oral
    • 6.8.2. Parenteral
  • 6.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2025
    • 6.9.1. Oral
    • 6.9.2. Parenteral
  • 6.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
    • 6.10.1. Hospital Pharmacies
    • 6.10.2. Retail Pharmacies
    • 6.10.3. Oncology Centers
  • 6.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2025
    • 6.11.1. Hospital Pharmacies
    • 6.11.2. Retail Pharmacies
    • 6.11.3. Oncology Centers
  • 6.12. Drivers and Restraints: Impact Analysis
  • 6.13. Market Attractiveness Analysis
    • 6.13.1. By Country
    • 6.13.2. By Drug Class
    • 6.13.3. By Route of Administration
    • 6.13.4. By Distribution Channel

7. Asia Pacific Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025

  • 7.1. Introduction
  • 7.2. Key Regulations
  • 7.3. Regional Market Dynamics
    • 7.3.1. Drivers
    • 7.3.2. Restraints
  • 7.4. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. India
    • 7.4.4. ASEAN
    • 7.4.5. Australia and New Zealand
    • 7.4.6. Rest of Asia Pacific
  • 7.5. Market Size (US$ Mn) Forecast By Country, 2017-2025
    • 7.5.1. China
    • 7.5.2. Japan
    • 7.5.3. India
    • 7.5.4. ASEAN
    • 7.5.5. Australia and New Zealand
    • 7.5.6. Rest of Asia Pacific
  • 7.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012-2016
    • 7.6.1. Premetrexed and combination
    • 7.6.2. Cisplatin and combination
    • 7.6.3. Carboplatin and combination
    • 7.6.4. Gemcitabine and combination
    • 7.6.5. Vinorelbine and combination
    • 7.6.6. Others combinations
  • 7.7. Market Size (US$ Mn) Forecast By Drug Class, 2017-2025
    • 7.7.1. Premetrexed and combination
    • 7.7.2. Cisplatin and combination
    • 7.7.3. Carboplatin and combination
    • 7.7.4. Gemcitabine and combination
    • 7.7.5. Vinorelbine and combination
    • 7.7.6. Others combinations
  • 7.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
    • 7.8.1. Oral
    • 7.8.2. Parenteral
  • 7.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2025
    • 7.9.1. Oral
    • 7.9.2. Parenteral
  • 7.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
    • 7.10.1. Hospital Pharmacies
    • 7.10.2. Retail Pharmacies
    • 7.10.3. Oncology Centers
  • 7.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2025
    • 7.11.1. Hospital Pharmacies
    • 7.11.2. Retail Pharmacies
    • 7.11.3. Oncology Centers
  • 7.12. Drivers and Restraints: Impact Analysis
  • 7.13. Market Attractiveness Analysis
    • 7.13.1. By Country
    • 7.13.2. By Drug Class
    • 7.13.3. By Route of Administration
    • 7.13.4. By Distribution Channel

8. Middle East & Africa Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025

  • 8.1. Introduction
  • 8.2. Key Regulations
  • 8.3. Regional Market Dynamics
    • 8.3.1. Drivers
    • 8.3.2. Restraints
  • 8.4. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
    • 8.4.1. GCC Countries
    • 8.4.2. South Africa
    • 8.4.3. North Africa
    • 8.4.4. Rest of MEA
  • 8.5. Market Size (US$ Mn) Forecast By Country, 2017-2025
    • 8.5.1. GCC Countries
    • 8.5.2. South Africa
    • 8.5.3. North Africa
    • 8.5.4. Rest of MEA
  • 8.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012-2016
    • 8.6.1. Premetrexed and combination
    • 8.6.2. Cisplatin and combination
    • 8.6.3. Carboplatin and combination
    • 8.6.4. Gemcitabine and combination
    • 8.6.5. Vinorelbine and combination
    • 8.6.6. Others combinations
  • 8.7. Market Size (US$ Mn) Forecast By Drug Class, 2017-2025
    • 8.7.1. Premetrexed and combination
    • 8.7.2. Cisplatin and combination
    • 8.7.3. Carboplatin and combination
    • 8.7.4. Gemcitabine and combination
    • 8.7.5. Vinorelbine and combination
    • 8.7.6. Others combinations
  • 8.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
    • 8.8.1. Oral
    • 8.8.2. Parenteral
  • 8.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2025
    • 8.9.1. Oral
    • 8.9.2. Parenteral
  • 8.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
    • 8.10.1. Hospital Pharmacies
    • 8.10.2. Retail Pharmacies
    • 8.10.3. Oncology Centers
  • 8.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2025
    • 8.11.1. Hospital Pharmacies
    • 8.11.2. Retail Pharmacies
    • 8.11.3. Oncology Centers
  • 8.12. Drivers and Restraints: Impact Analysis
  • 8.13. Market Attractiveness Analysis
    • 8.13.1. By Country
    • 8.13.2. By Drug Class
    • 8.13.3. By Route of Administration
    • 8.13.4. By Distribution Channel

9. Competition Landscape

  • 9.1. Competition Dashboard
  • 9.2. Company Profiles (Details - Overview, Financials, Strategy, SWOT, Recent Developments)
    • 9.2.1. AstraZeneca Plc.
    • 9.2.2. Bristol-Myers Squibb Company
    • 9.2.3. F. Hoffmann-La Roche Ltd.
    • 9.2.4. Merck & Co., Inc.
    • 9.2.5. Novartis AG
    • 9.2.6. Pfizer Inc.
    • 9.2.7. Sanofi
    • 9.2.8. Eli Lilly and Company
    • 9.2.9. Teva Pharmaceuticals
    • 9.2.10. Boehringer Ingelheim GmbH
    • 9.2.11. Mylan N.V.
    • 9.2.12. Fresenius Kabi AG
    • 9.2.13. Sun Pharmaceuticals Industries Ltd
    • 9.2.14. Corden Pharma International GmbH
    • 9.2.15. Concordia International Corp
    • 9.2.16. Kyowa Hakko Kirin Co Ltd.
    • 9.2.17. Polaris Pharmaceuticals, Inc.
    • 9.2.18. MolMed SpA
    • 9.2.19. Ono Pharmaceutical Co. Ltd
    • 9.2.20. Nichi-Iko Pharmaceutical Co., Ltd

10. Global Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025, By Region

  • 10.1. Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
    • 10.1.1. North America
    • 10.1.2. Latin America
    • 10.1.3. Europe
    • 10.1.4. Asia Pacific
    • 10.1.5. Middle East & Africa
  • 10.2. Market Size (US$ Mn) By Region, 2017-2025
    • 10.2.1. North America
    • 10.2.2. Latin America
    • 10.2.3. Europe
    • 10.2.4. Asia Pacific
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis By Region

11. Global Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025, By Drug Class

  • 11.1. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012-2016
    • 11.1.1. Premetrexed and combination
    • 11.1.2. Cisplatin and combination
    • 11.1.3. Carboplatin and combination
    • 11.1.4. Gemcitabine and combination
    • 11.1.5. Vinorelbine and combination
    • 11.1.6. Others combinations
  • 11.2. Market Size (US$ Mn) and Forecast By Drug Class, 2017-2025
    • 11.2.1. Premetrexed and combination
    • 11.2.2. Cisplatin and combination
    • 11.2.3. Carboplatin and combination
    • 11.2.4. Gemcitabine and combination
    • 11.2.5. Vinorelbine and combination
    • 11.2.6. Others combinations
  • 11.3. Market Attractiveness Analysis By Drug Class

12. Global Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration

  • 12.1. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
    • 12.1.1. Oral
    • 12.1.2. Parenteral
  • 12.2. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2025
    • 12.2.1. Oral
    • 12.2.2. Parenteral
  • 12.3. Market Attractiveness Analysis By Route of Administration

13. Global Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel

  • 13.1. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
    • 13.1.1. Hospital Pharmacies
    • 13.1.2. Retail Pharmacies
    • 13.1.3. Oncology Centers
  • 13.2. Market Size (US$ Mn) By Distribution Channel, 2017-2025
    • 13.2.1. Hospital Pharmacies
    • 13.2.2. Retail Pharmacies
    • 13.2.3. Oncology Centers
  • 13.3. Market Attractiveness Analysis By Distribution Channel

14. Global Malignant Mesothelioma Market Analysis 2012-2016 and Forecast 2017-2025

  • 14.1. Market Size and Y-o-Y Growth

List of Tables

  • Table 1: Pipeline Products (Phase I)
  • Table 2: Pipeline Products (Phase 1|Phase 2 and phase 2)
  • Table 3: Pipeline Products (Phase 2)
  • Table 4: Pipeline Products (Phase 2 and Phase 2|Phase 3)
  • Table 5: Pipeline Products ( Phase 3|4)
  • Table 6: List of orphan drugs in the pipeline for malignant mesothelioma
  • Table 7: Asbestos fiber Production (In Tonnes) 2011-2013
  • Table 8: Asbestos fiber consumption (In Tonnes) 2011-2013
  • Table 9: Epidemiology data of Malignant Mesothelioma 2015
  • Table 10: Reimbursement
  • Table 11: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
  • Table 12: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
  • Table 13: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
  • Table 14: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
  • Table 15: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
  • Table 16: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
  • Table 17: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
  • Table 18: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
  • Table 19: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
  • Table 20: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
  • Table 21: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
  • Table 22: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
  • Table 23: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
  • Table 24: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
  • Table 25: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
  • Table 26: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
  • Table 27: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
  • Table 28: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
  • Table 29: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
  • Table 30: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
  • Table 31: Global Malignant Mesothelioma Market Size (US$ Mn) 2012-2016 and Forecast 2017-2025 By Region,
  • Table 32: Global Malignant Mesothelioma Market Size (US$ Mn) 2012-2016 and Forecast 2017-2025 By Drug Type,
  • Table 33: Global Malignant Mesothelioma Market Size (US$ Mn) 2012-2016 and Forecast 2017-2025 By Route of Administration,
  • Table 34: Global Malignant Mesothelioma Market Size (US$ Mn) 2012-2016 and Forecast 2017-2025 By Distribution Channel,

List of Figures

  • Figure 1: North America Malignant Mesothelioma Market Value Share By Route of Administration (2017)
  • Figure 2: North America Malignant Mesothelioma Market Value Share By Drug type (2017)
  • Figure 3: North America Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
  • Figure 4: North America Malignant Mesothelioma Market Size Analysis, 2012-2016
  • Figure 5: North America Malignant Mesothelioma Market Size Analysis, 2017-2025
  • Figure 6: North America Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025
  • Figure 7: North America Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016-2025
  • Figure 8: U.S. Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 9: U.S. Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 10: Canada Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 11: Canada Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 12: North America Malignant Mesothelioma Market Attractiveness Analysis, By Country
  • Figure 13: North America Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
  • Figure 14: North America Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
  • Figure 15: North America Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
  • Figure 16: Latin America Malignant Mesothelioma Market Value Share By Route of Administration (2017)
  • Figure 17: Latin America Malignant Mesothelioma Market Value Share By Drug type (2017)
  • Figure 18: Latin America Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
  • Figure 19: Latin America Malignant Mesothelioma Market Size Analysis, 2012-2016
  • Figure 20: Latin America Malignant Mesothelioma Market Size Analysis, 2017-2025
  • Figure 21: Latin America Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025
  • Figure 22: Latin America Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016-2025
  • Figure 23: Brazil Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 24: Brazil Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 25: Mexico Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 26: Mexico Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 27: Rest of Latin America Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 28: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Country
  • Figure 29: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
  • Figure 30: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
  • Figure 31: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
  • Figure 32: Europe Malignant Mesothelioma Market Value Share By Route of Administration (2017)
  • Figure 33: Europe Malignant Mesothelioma Market Value Share By Drug type (2017)
  • Figure 34: Europe Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
  • Figure 35: Europe Malignant Mesothelioma Market Size Analysis, 2012-2016
  • Figure 36: Europe Malignant Mesothelioma Market Size Analysis, 2017-2025
  • Figure 37: Europe Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025
  • Figure 38: Europe Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016-2025
  • Figure 39: Germany Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 40: Germany Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 41: France Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 42: France Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 43: U.K. Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 44: U.K. Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 45: Spain Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 46: Spain Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 47: Italy Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 48: Italy Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 49: Russia Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 50: Russia Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 51: Rest of Europe Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 52: Rest of Europe Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 53: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Country
  • Figure 54: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
  • Figure 55: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
  • Figure 56: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
  • Figure 57: Asia-Pacific Malignant Mesothelioma Market Value Share By Route of Administration (2017)
  • Figure 58: Asia-Pacific Malignant Mesothelioma Market Value Share By Drug type (2017)
  • Figure 59: Asia-Pacific Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
  • Figure 60: Asia-Pacific Malignant Mesothelioma Market Size Analysis, 2012-2016
  • Figure 61: Asia-Pacific Malignant Mesothelioma Market Size Analysis, 2017-2025
  • Figure 62: APAC Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025
  • Figure 63: APAC Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016-2025
  • Figure 64: Japan Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 65: Japan Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 66: ANZ Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 67: ANZ Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 68: China Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 69: China Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 70: India Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 71: India Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 72: Rest of APAC Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 73: Rest of APAC Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 74: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Country
  • Figure 75: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
  • Figure 76: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
  • Figure 77: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
  • Figure 78: MEA Malignant Mesothelioma Market Value Share By Route of Administration (2017)
  • Figure 79: MEA Malignant Mesothelioma Market Value Share By Drug type (2017)
  • Figure 80: MEA Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
  • Figure 81: MEA Malignant Mesothelioma Market Size Analysis, 2012-2016
  • Figure 82: MEA Malignant Mesothelioma Market Size Analysis, 2017-2025
  • Figure 83: MEA Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025
  • Figure 84: MEA Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016-2025
  • Figure 85: GCC Countries Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 86: GCC Countries Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 87: South Africa Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 88: South Africa Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 89: Rest of MEA Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2025
  • Figure 90: Rest of MEA Malignant Mesothelioma Market Absolute $ Opportunity, 2017-2025
  • Figure 91: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Country
  • Figure 92: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
  • Figure 93: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
  • Figure 94: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
  • Figure 95: Global Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025
  • Figure 96: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016-2025
  • Figure 97: Global Malignant Mesothelioma Market Attractiveness Analysis By Region, 2017-2025
  • Figure 98: Global Malignant Mesothelioma Market Share Analysis (%) By Drug Type, 2017 & 2025
  • Figure 99: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By Drug Type, 2016-2025
  • Figure 100: Global Malignant Mesothelioma Market Attractiveness Analysis By Drug Type, 2017-2025
  • Figure 101: Global Malignant Mesothelioma Market Share Analysis (%) By route of administration, 2017 & 2025
  • Figure 102: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By route of administration, 2016-2025
  • Figure 103: Global Malignant Mesothelioma Market Attractiveness Analysis By route of administration, 2017-2025
  • Figure 104: Global Malignant Mesothelioma Market Share Analysis (%) By Distribution Channel, 2017 & 2025
  • Figure 105: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By Distribution Channel, 2016-2025
  • Figure 106: Global Malignant Mesothelioma Market Attractiveness Analysis By Distribution Channel, 2017-2025
  • Figure 107: Global Malignant Mesothelioma Market Value Analysis and Forecast, 2016-2025 (US$ Mn)
  • Figure 108: Global Malignant Mesothelioma Market Absolute $ Opportunity (US$ Mn), 2012-2016
  • Figure 109: Global Malignant Mesothelioma Market Absolute $ Opportunity (US$ Mn), 2016-2025